Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study (PEG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03394521|
Recruitment Status : Completed
First Posted : January 9, 2018
Last Update Posted : March 6, 2018
|Condition or disease||Intervention/treatment|
|Glaucoma||Other: Routine clinical practice|
In the UK, patients with possible signs of glaucoma or ocular hypertension (OHT) are usually picked up at a routine sight test at their optician or general practitioner. These patients are usually diagnosed in secondary care hospital eye services by an ophthalmologist.
In addition to those diagnosed with OHT and glaucoma there are a large group of patients who have ocular characteristics similar to those found in glaucoma patients, but could also represent variations in normality. In this group, 'glaucoma suspects', monitoring in secondary care for a number of years is recommended in order to establish whether they have glaucoma or if after several years of monitoring there are no clear signs of glaucoma the patient may be discharged.
In our study we will conduct a case-note review of a well-defined cohort of patients who were first identified through a diagnostic accuracy study (the GATE study). This includes (1) patients with OHT, (2) patients identified as glaucoma suspects and (3) patients diagnosed with glaucoma. We will investigate how many patients have experience worsening disease and how many patients have been discharged due to a low risk of glaucoma. We will also investigate the relationship between baseline demographic characteristics and characteristics of the eye and progression of disease.
|Study Type :||Observational|
|Actual Enrollment :||326 participants|
|Official Title:||Progression Evaluation in Glaucoma (PEG): Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study|
|Study Start Date :||October 2015|
|Actual Primary Completion Date :||August 2016|
|Actual Study Completion Date :||August 2016|
- Other: Routine clinical practice
This is an observational study
- Development of glaucoma [ Time Frame: 4 years ]Proportion of glaucoma suspects and OHT patients who develop glaucoma annually up to 4 years after diagnosis in secondary care
- Progression of glaucoma [ Time Frame: 1,2,3,4 years ]Proportion of the cohort of glaucoma patients with progression of disease up to 4 years
- Predictors of disease progression [ Time Frame: 4 years ]Evaluation of predictors of disease progression from baseline demographic and ocular characteristics
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03394521
|Principal Investigator:||Katie Banister||University of Aberdeen|